Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Multilevel decompression and bone graft fusion is a most effective measure for treating
degenerative lumbar spinal diseases. Yet, the surgery is commonly associated with large
amount of perioperative blood loss and high demand for homologous blood transfusion.
Tranexamic acid (TXA) has been proved as efficient in reducing the gross blood loss in
various kinds of surgeries. However, high quality evidence of its efficacy and safety is
still lacking in lumbar spinal surgeries. Besides, systemic use of TXA carries the risks of
thromboembolic complications such as deep venous thrombosis and pulmonary embolism, thus the
optimal drug delivery route of TXA remains undetermined. The aim of this study is to test the
non-inferiority of topical TXA application to its intravenous use in multilevel decompression
and bone graft fusion surgeries. A prospective, randomized, double-blind, head-to-head
comparison study design will be adopted.